GLP-1 drugs work by mimicking a natural gut hormone called GLP-1 (glucagon-like peptide-1) that your body releases after eating. This hormone acts on multiple systems at once: it triggers insulin release, suppresses appetite signals in the brain, and slows how fast food leaves your stomach. The medications are synthetic versions engineered to last much longer in the body than the natural hormone, which breaks down within minutes.
The Natural Hormone They’re Based On
Every time you eat, specialized cells in your intestine release GLP-1 into your bloodstream. This hormone is part of what’s called the “incretin effect,” a system that prepares your body to handle incoming nutrients. Natural GLP-1 tells your pancreas to release insulin, signals your brain that you’re getting full, and slows digestion so nutrients enter your bloodstream gradually rather than all at once.
The problem is that natural GLP-1 gets broken down by an enzyme in your blood within about two minutes. That’s too fast to be useful as a medication. GLP-1 drugs are structurally modified so they resist this breakdown. Depending on the specific drug, they last long enough to be taken once daily or once weekly. Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are both once-weekly injections. Liraglutide (Victoza, Saxenda) is a daily injection. An oral form of semaglutide (Rybelsus) is taken daily as a pill.
How They Control Blood Sugar
The pancreatic effects are the most well-studied part of how these drugs work. GLP-1 drugs bind to receptors on insulin-producing beta cells in the pancreas, prompting them to release more insulin when blood sugar is elevated. This is a critical distinction: the insulin release is glucose-dependent, meaning the drug only ramps up insulin production when blood sugar is actually high. When blood sugar drops to normal, the signal fades. This built-in safety mechanism makes dangerous blood sugar crashes far less likely than with older diabetes medications that push insulin out regardless of glucose levels.
At the same time, these drugs suppress glucagon, a hormone released by different pancreatic cells that raises blood sugar. In people with type 2 diabetes, glucagon is often inappropriately elevated, pushing the liver to dump glucose into the bloodstream even when it’s not needed. By dialing down glucagon, GLP-1 drugs help shut off that extra glucose production. The combination of more insulin when needed and less glucagon when it’s not creates a powerful two-pronged effect on blood sugar control.
Why They Reduce Appetite
GLP-1 receptors aren’t just in the pancreas. They’re also in brain regions that regulate hunger and reward. When GLP-1 drugs activate these receptors, they reduce appetite and create a feeling of fullness that makes it easier to eat less without constant willpower battles. People on these medications frequently describe a quieting of “food noise,” the persistent mental chatter about what to eat next.
This brain effect is separate from what happens in the gut. GLP-1 drugs slow gastric emptying, the rate at which food moves from your stomach into your small intestine. The mechanism appears to be neurally mediated, working through the vagus nerve that connects the gut to the brain. Slower stomach emptying means food sits longer, keeping you physically fuller after meals. It also blunts the sharp blood sugar spikes that typically follow eating, since nutrients trickle into the bloodstream more gradually.
Effects on the Liver and Metabolism
Beyond the pancreas and brain, GLP-1 drugs influence how the liver handles fat and sugar. They activate a cellular energy sensor that improves how liver cells respond to insulin, reduce the expression of genes involved in fat production, and lower the accumulation of fat in and around the liver. They also increase glucose uptake in the liver and muscles while lowering circulating free fatty acids.
These metabolic effects help explain why the drugs improve markers of metabolic health that go beyond what you’d expect from weight loss alone. Reductions in inflammation and oxidative stress have been observed independently of how much weight a person loses, suggesting the drugs are doing more than simply helping people eat less.
Cardiovascular Benefits
Large clinical trials have shown that GLP-1 drugs reduce the risk of major cardiovascular events, including heart attack, stroke, and cardiovascular death. A meta-analysis of eight major trials found a 14% reduction in these combined events. The benefit appears to come from multiple pathways: lower blood sugar, weight loss, reduced inflammation, and possibly direct effects on blood vessels. These cardiovascular benefits are one reason the drugs have become important beyond diabetes treatment alone.
How Dual Agonists Differ
Tirzepatide (sold as Mounjaro for diabetes and Zepbound for weight loss) works differently from pure GLP-1 drugs. It activates two hormone receptors instead of one: the GLP-1 receptor and the GIP receptor. GIP is another incretin hormone released after eating, and it has its own effects on insulin release, fat metabolism, and appetite.
Tirzepatide actually favors GIP receptor activity over GLP-1 activity. It binds the GIP receptor with equal strength to the natural hormone but binds the GLP-1 receptor about five times more weakly than natural GLP-1. At the GLP-1 receptor, it behaves as a partial agonist, reaching only about 51% of the full signaling capacity. It also triggers less receptor internalization, a process where the receptor gets pulled inside the cell and temporarily stops working. This different signaling profile may contribute to why tirzepatide has produced larger weight loss results in clinical trials than pure GLP-1 drugs, though the exact reasons are still being studied.
Common Side Effects and Why They Happen
Gastrointestinal side effects are the most common issue, and they’re a direct consequence of how the drugs work. Slowing stomach emptying and activating GLP-1 receptors in the brain’s nausea centers can cause nausea, vomiting, diarrhea, and constipation. In a major trial of semaglutide 2.4 mg weekly, a cumulative 33.7% of participants reported nausea over the study period. Between 6 and 10% of patients discontinue treatment because of these effects, and roughly 15% need a dose reduction.
The good news is that these side effects are usually worst at the beginning and improve substantially. The most pronounced effects occur when starting the medication or increasing the dose, then tend to fade over the first 90 days as the body adjusts. This is why all GLP-1 drugs use a gradual dose escalation schedule, starting low and increasing over weeks to months.
Interestingly, patients on tirzepatide report slightly fewer GI side effects overall (40%) compared to those on semaglutide (43%), with lower rates of nausea (17.4% vs. 19.2%) and notably less vomiting (5.7% vs. 8.1%). The GIP receptor activity in tirzepatide may help buffer some of the nausea driven by GLP-1 receptor activation, though this relationship is still being explored. Early research suggests that the nauseating effects and the appetite-reducing effects of GLP-1 drugs may not be as tightly linked as previously assumed, meaning it may eventually be possible to preserve the weight loss benefits while further minimizing the GI discomfort.